Last reviewed · How we verify
Diphenylcyclopropenone
Diphenylcyclopropenone is a Small molecule drug developed by Rockefeller University. It is currently in Phase 2 development. Also known as: Diphencyprone, DPCP.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Diphenylcyclopropenone |
|---|---|
| Also known as | Diphencyprone, DPCP |
| Sponsor | Rockefeller University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases (PHASE1)
- DPCP for the Treatment of Alopecia Areata (PHASE3)
- Trem-1 and Ultraviolet Radiation-induced Immune Suppression (EARLY_PHASE1)
- DPCP to Treat Cutaneous Neurofibromas Associated With NF1 (PHASE1)
- Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo (PHASE4)
- Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers (NA)
- Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (PHASE1)
- Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diphenylcyclopropenone CI brief — competitive landscape report
- Diphenylcyclopropenone updates RSS · CI watch RSS
- Rockefeller University portfolio CI
Frequently asked questions about Diphenylcyclopropenone
What is Diphenylcyclopropenone?
Who makes Diphenylcyclopropenone?
Is Diphenylcyclopropenone also known as anything else?
What development phase is Diphenylcyclopropenone in?
Related
- Manufacturer: Rockefeller University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Diphencyprone, DPCP
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing